Lead Product(s) : AR101
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Peanut Oral Immunotherapy Study of Early Intervention for Desensitization
Details : AR101 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Peanut Hypersensitivity.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 09, 2018
Lead Product(s) : AR101
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AR101
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Real World, Open Label, QOL Assessment of Peanut Immunotherapy AR101 in Children and Adolescents
Details : AR101 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Peanut Hypersensitivity.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 12, 2018
Lead Product(s) : AR101
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AR101
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
AR101 Real-World Open-Label Extension Study
Details : AR101 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Peanut Hypersensitivity.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 09, 2017
Lead Product(s) : AR101
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AR101
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Longer-term Study of AR101 in Subjects Who Participated in a Prior AR101 Study (ARC008)
Details : AR101 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Peanut Hypersensitivity.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 25, 2017
Lead Product(s) : AR101
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AR101
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
ARTEMIS Peanut Allergy In Children
Details : AR101 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Peanut Hypersensitivity.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 28, 2017
Lead Product(s) : AR101
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AR101
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Real-World AR101 Market-Supporting Experience Study in Peanut-Allergic Children (RAMSES)
Details : AR101 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Peanut Hypersensitivity.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 24, 2017
Lead Product(s) : AR101
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AR101
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
PALISADE Follow-on Study (ARC004)
Details : AR101 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Peanut Hypersensitivity.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 15, 2016
Lead Product(s) : AR101
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AR101
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AR101 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Wounds and Injuries.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 20, 2016
Lead Product(s) : AR101
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AR101
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AR101 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Peanut Hypersensitivity.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 21, 2015
Lead Product(s) : AR101
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AR101
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase II
Sponsor : Cato Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety and Efficacy of AR/101 in Accelerating Re-epithelialization of Split Thickness Wounds
Details : AR101 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Wounds and Injuries.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 11, 2015
Lead Product(s) : AR101
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase II
Sponsor : Cato Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
